- All
- Product Name
- Product Keyword
- Product Model
- Product Summary
- Product Description
- Multi Field Search
 |
product description
Chlorogrene (Waveiwei) is a common drug for preventing and treating blood, brain and other arterial circulating disorders caused by platelet height, such as stroke, myocardial infarction, etc. Clinical practice shows that there are differences in the efficacy and poisonous side effects of different patients to take clopidogrel. The root cause is that the clopidogrel metabolic enzyme CYP2C19 gene is different, which leads to different CYP2C19 enzyme activity, affecting clopidogrel metabolism, this gene is also Omphrazole and other drug metabolism related.
The highest frequency of frequent frequency in the Chinese population is the 5th exon 681g> A (ie CYP2C19 * 2) and the fourth exon 636g> a (ie CYP2C19 * 3), when the two sites are varied CYP2C19 enzyme activity is lowered, and the drug metabolism is slow metabolites. Such patients are taking drugs by CYP2C19 enzyme metabolism (Ometrazole, etc.), while taking precursor drugs (clopidogrel, etc.) It is not good or invalid because of less the formation of metabolites. Another polymorphism is -806c> t (i.e., CYP2C19 * 17), which is expressed as an increase in CYP2C19 enzyme activity when the site is changed.
On March 12, 2010, the US Food and Drug Administration (FDA) added a \"black frame warning \" on its metabolic non-incompatibility in the drug instructions of clopidogrel, focusing on the regulation of clopidogrel on such patients. The important meaning and feasibility of genetic testing of metabolism (CYP2C19), and adjustments to the corresponding antiplatelet strategy.
product information
Tianlong Technology clopidogrel Independent medication solution is based on microose techniques for special ligase and fluorescent capture probes, using Tianlong micro-measurement reagents and Fascan fluorescent quantitative analyzers, can quickly obtain clopidogrel metabolism related genes Site information: CYP2C19 * 2 (C.681G> a), CYP2C19 * 3 (C.636G> a), CYP2C19 * 17 (-806C> T), used to guide clopidogrel and Omerazole and other individualization Medicate.
Program advantage
•Convenient operation: Sample free extraction, and reagents are pre-blended, only one step is taken, 40 minutes can be obtained.
•The hardware requirement is low: no nucleic acid extraction equipment and large sequencing equipment are required, and the general laboratory can be satisfied.
•Judging precision: powerful automatic judgment software, no subjective factors, ultimately output results in the form of a single form.
• The result is reliable: the sample has internal quality control system to ensure reliable output results.
• The reagents can be customized: testing projects can be customized to meet your personalized needs.
Clinical significance
To guide chlorogrene, oleralrazole, etc., prevent thrombosis or bleeding, and reduce poisonous side effects.
For people
●Coronary heart disease, thrombosis patient
●Patients with recirculating disorders after bracketing and catheter surgery
Genetic site and metabolic
Metabolic | Genotype and specific location information | ||
-806 | 636 | 681 | |
Super fast metabolism | C / T | G / g | G / g |
T / T | G / g | G / g | |
Fast metabolism | C / C | G / g | G / g |
Medium and metabolism | C / C | G / g | A / g |
C / C | A / g | G / g | |
Slow metabolism | C / C | G / g | A / a |
C / C | A / A | G / g | |
C / C | A / g | A / g | |
C / C | A / g | A / a | |
C / C | A / a | A / g | |
C / C | A / A | A / a | |
